Fortuna Fix, a Laval (QC) Canada-based clinical-stage regenerative medicine company, closed a $25m Series B financing.
Amgen Ventures and other new investors joined existing shareholders Salamander Invest. In conjunction with the investment by Amgen Ventures, Dr. John Dunlop (Ph.D), Amgen Vice President, Neuroscience Discovery Research, and Philip Tagari, Amgen Vice President, Therapeutic Discovery, will take the roles of Scientific Advisory Board member and Board observer at Fortuna, respectively.
The company intends to use the proceeds to conduct Phase I/IIa clinical trials in Parkinson’s Disease and Spinal Cord Injury and further expand automated robotic manufacturing capabilities.
Led by Jan-Eric Ahlfors, CEO and CSO, Fortuna Fix is advancing a patented direct cell reprogramming technology platform (drNPC) and a proprietary bio-scaffolding technology (RMx™), for the treatment of neurodegenerative diseases and neurotrauma. The company is focused on its lead programs in Spinal Cord Injury and Parkinson’s disease with further development efforts in Stroke, Traumatic Brain Injury, Hearing Loss and ALS.
The company has developed a proprietary, large-scale and fully automated GMP manufacturing system for production of autologous drNPCs.